DUBLIN, June 14, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
"As the Campbell family understands firsthand, it is critical that families of people with Alzheimer's disease know where to turn for help and support," said Charles J. Fuschillo, Jr., AFA's president and chief executive officer. "Care and support are how we can make a difference in helping the millions of individuals living with Alzheimer's and for their families."
Allergan also announced the launch of a new caregiver resource website, CaringforAlzheimers.net. The site is an online resource where caregivers can find out more information about the symptoms of Alzheimer's disease. The site features tools that caregivers can use to effectively communicate with their loved one's doctor, including a symptoms tracker that can be filled out to help track disease progression.
"Alzheimer's disease is a progressive, neurodegenerative disorder that is complex, particularly when patients enter the moderate stage of the disease," says Gavin Corcoran, M.D., chief medical officer. "At Allergan, we're proud to support programs that provide more information and offer resources to guide patients and caregivers as they navigate the disease."
More than 5.1 million people in the U.S. may have Alzheimer's disease.1 According to a U.S.-based survey, nearly 50 percent of patients with Alzheimer's disease are already in the moderate to severe stages at the time of diagnosis.2 For more information about the initiatives, visit AlzFdn.org or CaringforAlzheimers.net.
About Allergan Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.allergan.com.
About Alzheimer's Foundation of America (AFA) The Alzheimer's Foundation of America, based in New York, is a non-profit organization that unites more than 2,500 member organizations nationwide with the goal of providing optimal care and services to individuals living with dementia, and to their caregivers and families. Its services include a national, toll-free helpline (866-232-8484) staffed by licensed social workers, educational materials, a free quarterly magazine for caregivers and "AFA Partners in Care" dementia care training for healthcare professionals. For more information about AFA, call 866-232-8484, visit www.alzfdn.org, follow us on Twitter, or connect with us on Facebook or LinkedIn.
Forward-Looking Statement Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended March 31, 2016(certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
1. "About Alzheimer's Disease: Statistics" Alzheimer's Foundation of America. Accessed June 2016. http://www.alzfdn.org/AboutAlzheimers/statistics.html. 2. "Alzheimer's Disease Physician Study." GfK Healthcare. 2013.
Fran DeSena (973) 517-3132
Mark Marmur (862) 261-7558
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-reaches-out-to-family-caregivers-of-people-with-alzheimers-disease-with-new-psa-website-300284125.html
SOURCE Allergan plc
Subscribe to our Free Newsletters!
Schizoaffective disorder is a serious mental disorder in which the individual reflects symptoms ...
When a person overeats, he is unable to control his hunger pangs, while during an emotional/binge ...
Hypoplastic left heart syndrome is a rare congenital condition, which affects normal blood ...View All